CARL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Carlsmed Inc (CARL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with increased price targets, positive news catalysts, and a promising growth outlook. While the technical indicators are mixed, the company's advancements in personalized surgical technology and its upcoming earnings report provide a solid foundation for long-term growth.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 66.643, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 12.85, and support is at 10.86. The stock shows a 60% chance of gaining 18.35% in the next month, suggesting potential upside.
Carlsmed's successful first personalized cervical plating procedure and plans for commercial launch later this year. Analysts have raised price targets, showing confidence in the company's future performance. The stock has a Buy rating with an average price target of $20.25.
Additionally, moving averages indicate a bearish trend.
In Q3 2025, revenue remained flat at $13,074,000 YoY. Net income was -$8,526,000, with an EPS of -0.4. Gross margin increased to 75.93%, which is a positive sign for operational efficiency.
Analysts are optimistic, with Goldman Sachs raising the price target to $20 and maintaining a Buy rating. UBS and Deutsche Bank have also upgraded the stock recently, citing growth potential and a return to consistent volume growth in key markets.
